The tumor suppressor gene product p53 can bind to and inhibit the helicase activity of the multisubunit transcription-repair factor TFIIH. We previously reported that p53-mediated apoptosis is attenuated in primary human ®broblasts from individuals with Xeroderma Pigmentosum (XP) that harbor mutations in the TFIIH DNA helicases XPD or XPB. In this study we show that apoptosis is reduced and delayed in three XPD lymphoblastoid cell lines (LCLs), but not in an XPD heterozygote LCL, after exposure to doxorubicin, a DNA-damaging agent and topoisomerase II inhibitor frequently used in cancer therapy. Apoptosis was assessed by quantitation of Annexin V binding to exposed phosphatidylserine residues and by caspasemediated cleavage of Poly(ADP)Ribose Polymerase (PARP). Apoptosis induced by doxorubicin was suppressed in LCLs retrovirally transduced with the Human Papillomavirus 16 E6 oncoprotein, consistent with the hypothesis that this is a p53-dependent process. PARP cleavage was not delayed in XPD LCLs in response to anti-Fas (CD95) antibody-mediated apoptosis, thus, the defect in the apoptotic pathway in these cells lies upstream of caspase activation. Similar changes in the expression of apoptosis-eector genes, p53, and p53-responsive genes p21
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Introduction
The XPD gene encodes an ATP-dependent 5' to 3' DNA helicase found as a subunit of TFIIH, an enzyme complex that has a role in nucleotide excision repair (NER), basal transcription and possibly cell cycle control (Svejstrup et al., 1996) . XPD is essential for cell viability, since XPD-null mouse embryos do not progress beyond the two-cell stage (de Boer et al., 1998a) . Mutations in XPD increase the UV-sensitivity and predispose to the sunlight-induced skin cancers that are associated with Xeroderma Pigmentosum group D (XPD). Mutations in this gene have also been detected in the much less cancer-prone syndrome Trichothiodystrophy (TTD/XPD) (Stary and Sarasin, 1996) . The dierence in cancer proneness may be due to speci®c allelic mutations in XPD altering the DNA repair and transcription functions of TFIIH differentially (Lehmann, 1995; Stary and Sarasin, 1996) . Thus, TTD/XPD mutations could be associated with subtle transcriptional de®ciencies in addition to the repair defect. Support for the transcription de®ciency hypothesis comes from the recent ®nding that speci®c allelic mutations seem to segregate with either XPD or TTD/ XPD clinical features (Taylor et al., 1997) . Furthermore, mice that were developed mimicking a speci®c TTD/XPD mutation showed reduced constitutive transcription of the skin gene SPRR2 that correlated with the development of TTD skin symptoms (de Boer et al., 1998b) . These ®ndings further strengthen the hypothesis that reduced basal transcription from TFIIH may be responsible for at least some of the overt features of TTD/XPD and possibly XPD syndromes.
The tumor suppressor gene product p53 is a central component of the stress-activated pathway that controls cell growth and death after DNA damage, leading to either a transient arrest in cell growth or a permanent senescent-like arrest or apoptosis (reviewed by Levine, 1997) . p53 is normally present in a latent form at low levels, but upon a variety of environmental insults, such as radiation, chemotherapeutic drugs, ribonucleotide depletion, or hypoxia, p53 accumulates and is activated as a transcription factor. Recent reports suggest that certain post-translational modifications of p53, including site-speci®c phosphorylation or acetylation, might mediate responses to particular types of damage (reviewed by Prives, 1998) . For example, exposure to UV, but not IR, leads to phosphorylation of serine 392 of human p53 (Kapoor and Lozano, 1998; Lu et al., 1998) through CKII-dependent and -independent pathways (Blaydes and Hupp, 1998) , whereas exposure to either UV or IR leads to phosphorylation of serine 15 Siliciano et al., 1997) , possibly mediated by the kinases ATM and/or DNA-PK (Banin et al., 1998; Canman et al., 1998) .
Growth arrest mediated by p53 has been clearly correlated with its function as a sequence-speci®c transcriptional activator of p21
(p21), a cyclin-dependent kinase inhibitor (Harper et al., 1993; el-Deiry et al., 1993; Noda et al., 1994) . p21 prevents phosphorylation of the retinoblastoma protein (pRb) in late G1 phase of the cell cycle through inactivation of a G1 cyclin/cyclin-dependent kinase complex. The underphosphorylated form of pRb maintains cells in G1 by sequestering the transcription factor E2F, thereby preventing the transcription of genes necessary for S-phase entrance.
The mechanism of induction of apoptosis by p53 is at least partially mediated by its transactivation function as well. Activated p53 can promote transcription of genes involved in apoptosis. Among them, bax, whose product dimerizes with Bcl-2 and prevents Bcl-2 from blocking apoptosis (Miyashita and Reed, 1995) ; IGFBP3, encoding an antagonist of insulin-like growth factor-1 (IGF-1) (Buckbinder et al., 1995) ; and, possibly, CD95/Fas/APO1 (Friesen et al. 1996; Sheard et al., 1997) and KILLER/DR5 (Sheik et al., 1998), whose products can activate cell surface receptormediated apoptosis. Even though these genes can be transcriptionally activated by p53, their contribution to the induction of apoptosis is complex. Furthermore, not only is the transactivation function alone not sucient for induction of p53-mediated apoptosis (Gottlieb et al., 1996) , but fragments of p53 that are incapable of transactivation can eciently induce apoptosis themselves (Haupt et al., 1995; Wang et al., 1996) . These observations indicate that a putative transactivation-independent pathway of apoptosis might be regulated by p53 as well.
In addition to the growth arrest and cell death functions associated with p53, functional interactions between p53 and the NER machinery are now becoming apparent. It was recently shown that the Cterminal domain of p53 binds and inhibits the helicase activity of the TFIIH complex (Wang et al., 1995; Leveillard et al., 1996) . Fibroblasts that are p53-null are less ecient in removal of UV-induced photoproducts (Wang et al., 1995; Ford and Hanawalt, 1995) and exhibit less UV-induced apoptosis (Ford and Hanawalt, 1995) . Conversely, expression of wild-type p53 can enhance NER in p53-null ®broblasts (Ford and Hanawalt, 1997) . Moreover, induction of p53-dependent apoptosis is attenuated in XPD and XPB ®broblasts, but can be rescued by wild type XPD or XPB, respectively (Wang et al., 1996) . These results are consistent with the hypothesis that reduced eciency of the DNA repair and apoptotic pathways would enhance chromosomal instability and mutagenesis, leading to malignant transformation.
The hypothesis of the current study is that if XPD functionally interacts with the p53-mediated apoptotic pathway, then doxorubicin-induced apoptosis will be de®cient in lymphoblastoid cell lines (LCLs) derived from XPD patients. Doxorubicin is an anthracycline derivative frequently used in cancer therapy. It has high anity for DNA, and accumulates in the nucleus soon after treatment of cells in culture. Its mechanism of action is a complex combination of intercalation into DNA, leading to topoisomerase II inhibition, metabolic activation and DNA-adduct formation (Speth et al., 1998) . It has been reported that the antitumor activity of this compound is largely mediated by induction of apoptosis through wild-type p53 (Lowe et al., 1994) .
Here, we show that apoptosis induced by doxorubicin is delayed and reduced in three XPD LCLs when compared to three normal LCLs. An XPD heterozygote LCL derived from the unaected parent of one of those XPD patients responded with normal kinetics to the same treatment. Normal and XPD LCLs showed a similar induction of stress and apoptosis-related genes upon treatment, indicating that dierential transcription of at least a subset of such eector genes was not responsible for such dierence in response. Caspase-mediated cleavage of Poly(ADP)Ribose Polymerase (PARP) was further suppressed in LCLs retrovirally transduced with the HPV E6 oncoprotein, consistent with the hypothesis that this process is dependent on p53. Moreover, XPD LCLs responded normally to Fas-antibody induced apoptosis, which does not involve p53 stabilization. Thus, these studies are consistent with the hypothesis that XPD and p53 can functionally interact in a p53-mediated apoptotic pathway. Additional studies of expression of other genes transcriptionally regulated by p53 are needed to determine the contribution of either transcriptionally dependent or independent pathways to p53-mediated apoptosis.
Results

Selection of the dose of doxorubicin
In order to determine the optimum dose of doxorubicin for induction of apoptosis in LCLs, we ®rst performed a dose-response viability curve using the normal LCL C3ABR (Figure 1 ). Dose-dependent loss of cell viability was evident within 24 h ( Figure 1a ). Although doses of 1.0 and 10.0 mg/ml doxorubicin resulted in similar loss of cell viability, only at the 1.0 mg/ml dose was there a signi®cant proportion of cells that showed chromosomal condensation and DNA fragmentation characteristic of programmed cell death ( Figure 1b ). Similar lack of typical DNA fragmentation at high doses of doxorubicin has been observed in human leukemia T-cell lines (Friesen et al., 1996) . In addition, although p53 was maximally induced by 10.0 mg/ml doxorubicin, expression of p53-responsive genes p21 ( Figure 1c ) and GADD45 (not shown) was inhibited at this dose. These results indicate that cell death at the highest dose might be due to non-speci®c transcriptional shut-down rather than by p53-mediated apoptosis. Thus, 1.0 mg/ml doxorubicin was selected to study the putative dierence in p53-dependent apoptotic response between normal and XPD LCLs.
Apoptosis is reduced and delayed in XPD LCLs
Apoptosis was quantitated within 24 h after treatment with 1.0 mg/ml doxorubicin by FACScan analysis of Annexin V-FITC binding. Annexin V binding to phosphatidylserine residues in the cell membrane is an early marker of apoptosis. The average of three independent experiments of time-dependent induction of Annexin V-FITC binding in three normal and three XPD LCLs is depicted in Figure 2a . Speci®c apoptosis was reduced and delayed in all XPD LCLs compared to the normal LCLs. This dierence was statistically signi®cant when all XPD LCLs were compared as a group to each of the normal LCLs independently (Friedman ANOVA, P50.05 in all cases). In each case, the presence of morphological features of apoptosis was veri®ed under the microscope in DAPIstained cells (not shown).
Site-speci®c cleavage of PARP was used as an independent marker of apoptosis. PARP is a nuclear Zn 2+ -dependent 116 kDa DNA binding protein that recognizes DNA strand breaks produced by various DNA damaging agents and adds poly-ADP-ribose to itself and other nuclear proteins as part of the DNA repair response (Lindahl et al., 1995) . PARP is a substrate for Caspase-3, and its cleavage is an early event in the apoptotic response, correlating with or even preceding the ability to detect actual DNA fragmentation (Wolf et al., 1997) . Degradation of PARP also occurs in necrosis, but site-speci®c cleavage that produces an 89 kDa fragment from the 116 kDa full length protein is considered a hallmark of apoptosis (Shah et al., 1996) . The time of appearance and proportion of cleaved product correlated with the increase in doxorubicin-induced apoptosis measured by Annexin V-FITC binding in both normal and XPD LCLs (Figure 2b) . These results validate the use of PARP cleavage as a bona ®de indicator of caspase activation in drug-induced apoptosis. The 89 kDa caspase-cleaved fragment of PARP appeared within 6 h of treatment in normal LCLs, but later than 12 h after treatment in XPD LCLs. This delay is consistent with the¯ow cytometry data shown previously ( Figure  2a ). p53 protein stabilization was observed in both normal and XPD LCLs by 6 h after treatment ( Figure  2b ), indicating that the molecular basis for the delayed response to doxorubicin must lie in factors downstream of p53.
Normal kinetics of apoptosis in an XPD heterozygote LCL
The lack of a common genetic background in the normal and XPD cell lines studied above raises the possibility that intrinsic variability of the cell lines, rather than XPD de®ciency, may be responsible for the delay and reduction in apoptosis. In order to clarify this issue, we have obtained a cell line derived from an unaected progenitor of one of those XPD patients. Apoptotic cell death in response to doxorubicin Expression of p53-responsive genes in whole cell extracts at the indicated time points after doxorubicin treatment. PCNA was used as loading control treatment was followed by appearance of a caspasespeci®c PARP cleavage product in the XPD heterozygote LCL, GM02473A, its related XPD LCL, GM02253F, and two unrelated normal LCLs, HG1943 and C3ABR (Figure 3) . PARP cleavage was delayed in GM02253F (Figure 3a ) with respect to normal LCLs (Figure 3b ), as observed previously (Figure 2b ). However, PARP cleavage followed the same kinetics in the XPD heterozygote LCL GM02473A (Figure 3a) , as in normal cell lines (Figure 3b) . In a separate experiment, speci®c apoptosis was measured by FACScan analysis of Annexin V-FITC binding. The percentages of apoptosis at 24 h after doxorubicin treatment were as follows: HG1943, 51+1%; GM02253F, 26+3%; GM02473A, 43+5%. By One-way ANOVA, followed by a multiple comparison test, there was statistically signi®cant dierence in apoptosis between the XPD LCL GM02253F and both the normal LCL HG1943 and the XPD heterozygote LCL GM02473A (P50.01), but not among HG1943 and GM02473A (P40.05). Therefore, the delay and reduction in apoptosis was observed in an XPD cell line even in conditions of a low genetic variability, supporting the hypothesis that XPD mutations can modulate p53-mediated apoptosis.
Transcription of apoptosis-related genes is similar in normal and XPD LCLs
XPD and XPD/TTD clinical features may be related to subtle transcriptional de®ciencies due to speci®c mutations in the XPD gene (Lehmann, 1995; Stary and Sarasin, 1996) . To determine if transcriptional de®ciencies could be involved in the reduced apoptotic response of XPD LCLs, we analysed transcription of p53-regulated genes and apoptosis-speci®c genes by RNase protection (Figure 4a) . Expression of the stressactivated genes p53, p21, GADD45, Bax and Bcl-X was similarly upregulated by doxorubicin in normal and XPD LCLs (Figure 4b) . Expression of c-fos and bcl-2, was undetectable in all of the cell lines, and mcl1 message was unchanged by treatment. In addition, no XPD genotype-speci®c dierences were observed in the transcription of the apoptosis eector genes Flice, FasL, Fas, Fadd, DR3, FAP, FAF, TRAIL, TNFRp55, TRADD, RIP, Granzyme B, Mch2, ICErel-III, ICH-1, Mch3, ICE, and ICELap6, (hAPO-1 and hAPO-3 template sets, Pharmingen, not shown). These results indicate that XPD cells are not de®cient in transcription of at least this subset of stress-activated and apoptosis eector genes.
Fas-mediated caspase activation is normal in XPD LCLs
Resistance to doxorubicin-induced apoptosis in XPD LCLs could be due to a general defect in the pathway leading to irreversible caspase activation rather than a speci®c defect in a p53-mediated apoptotic pathway. Thus, it was important to determine if XPD LCLs were pro®cient in an apoptotic pathway not mediated by p53. To this end, we compared Fas-mediated apoptosis in one normal and one XPD LCL, using induction of PARP cleavage as an indicator of caspase activation during the early stages of apoptosis. Incubation with antiFas (CD95) antibody CH-11 resulted in similar timedependent induction of PARP cleavage in normal and XPD LCLs ( Figure 5 ). This event occurred much more rapidly (within 2 h of antibody treatment) in Fas-treated LCLs than in doxorubicin-treated LCLs. Accumulation of p53 was observed in response to doxorubicin treatment but not to anti-Fas antibody treatment, consistent with the premise that p53 activation is not required for Fas-mediated apoptosis. We conclude from this result that the Fasmediated apoptotic machinery is functional in XPD cells, and that the de®ciency observed after doxorubicin treatment must lie upstream of caspase activation.
Doxorubicin-induced apoptosis is dependent on p53 accumulation
Although it is widely accepted that cell death after doxorubicin treatment is primarily dependent on the presence of wild-type p53, this has only been proved for some cell types (Lowe et al., 1994) and has not been formally shown in LCLs. Because the hypothesis of this work relies on the mode of death being mediated by p53, we generated normal and XPD LCLs expressing HPV 16 E6 and/or a neo marker. The E6 oncoprotein can bind to p53 and hasten its degradation by the ubiquitin system (Schener et al., 1990) . As expected, p53 accumulation was induced by doxorubicin in the neo-only derivatives ( Figure 6 ) as it was in their respective parental cell lines (Figure 2b) . Figure 3 Normal kinetics of caspase activation in an XPD heterozygote LCL. Analysis of p53 expression and PARP cleavage in whole cell lysates of doxorubicin-treated XPD heterozygote LCL, GM02473A and its related XPD LCL, GM02253F (a), and two unrelated normal LCLs, HG1943 and C3ABR (b). Actin was used as loading control p53 accumulation was detectable only after a long exposure in HG1943-E6 (Figure 6a ) and GM02253F-E6 (Figure 6b ) and reduced in several orders of magnitude with respect to their neo controls. In addition, p21 protein was not induced in either E6-derivative, indicating that p53 is transcriptionally inactive (data not shown). PARP cleavage was evident at 6 h in HG1943-neo, consistent with the parental cell line, but was undetectable within 24 h in HG1943-E6 (Figure 6a ). In the case of GM02253F (XPD), PARP cleavage was delayed in the neo-only derivative like in the parental cell line, and it was also undetectable in the E6-expressing derivative (Figure 6b ). These results indicate that PARP cleavage and, therefore, caspase activation and apoptosis occurring within the ®rst 24 h after doxorubicin treatment are dependent on p53 accumulation. After prolonged exposure to the drug, however, p53-independent cell death pathways might also play a role.
Discussion
The apoptotic function of p53 is important in carcinogenesis and cancer therapy (Levine, 1997) . However, the speci®c downstream signaling pathways in p53-mediated apoptosis leading to the irreversible activation of executioner caspases are, as yet, not well- Figure 4 Transcription of p53-inducible genes in doxorubicin-treated normal and XPD LCLs. (a) RNAse protection assay using the 32 P-labeled multiprobe template set hStress-1. (b) Induction of mRNA species relative to levels at 0 h using GAPDH as an internal control. Open symbols represent XPD cell lines de®ned. Several lines of research have provided evidence for the existence of at least two apparently independent pathways for induction of apoptosis mediated by p53 (Levine, 1997) . The best-studied pathway relies on p53's function as a transcription factor. This transactivation-dependent apoptosis is initiated by p53-mediated activation of apoptosiseector genes, like bax (Miyashita and Reed, 1995) , IGFBP3 (Buckbinder et al., 1995) and possibly CD95/ Fas/APO1 (Friesen et al., 1996; Sheard et al., 1997) and KILLER/DR5 (Sheikh et al., 1998) . Expression of these genes has been correlated with p53 accumulation during various stress responses and is believed to contribute to p53-mediated apoptosis. It is clear, however, that p53-mediated apoptosis is not exclusively dependent on the regulation of gene transcription by p53. A p53 gene competent in transactivation can mediate growth factor withdrawal-dependent apoptosis without activation of p53-responsive promoters (Gottlieb et al., 1996) . In addition, p53 mutants that lack transactivation function, such as a mutant containing the 214 amino-terminal residues of p53 (Haupt et al., 1995) and a p53 carboxy-terminal peptide containing the helicase binding domain (Wang et al., 1996) can eciently induce apoptosis. These observations indicate that a putative transactivation-independent pathway of apoptosis might be regulated by p53 as well.
In the present study, we extend previous observations that apoptosis driven by ectopic expression of p53 was prevented in primary human ®broblasts derived from XPD patients (Wang et al., 1996) to show that apoptosis induced by stabilization of endogenous p53 is also aected in XPD individuals. The dependence of doxorubicin-induced apoptosis on p53 stabilization was demonstrated by the delay in caspase-mediated cleavage of PARP in normal and XPD LCLs expressing HPV 16 E6 oncoprotein. It has been reported that other proteins are also targets for E6 binding (Kubbutat and Vousden, 1998), however, these other factors are unlikely to contribute to the observed reduced and delayed response to doxorubicin treatment in XPD LCLs. The percentage of apoptosis measured by Annexin V binding correlated in each case with PARP cleavage in both normal and XPD LCLs. Furthermore, the delay observed in PARP cleavage in XPD LCLs strongly supports the quantitative data obtained by¯ow cytometry. Validation of the use of caspase-3 activation as an indicator of apoptosis in LCLs has also been recently reported in irradiated LCLs (Yu and Little, 1998) . In this case, the expression of HPV 16 E6 oncoprotein in a normal LCL also resulted in delayed and reduced caspase activation, PARP cleavage, and apoptosis.
It has been hypothesized that mutations in the XPD gene can aect the conformation of the TFIIH complex and thus lead to either reduced or aberrant gene transcription. The screening of some candidate genes, selected because they were either inducible by p53 or part of the executioner phase of the apoptotic machinery, yielded no XPD genotype-speci®c differences at the level of gene transcription. In view of the recent report of reduced constitutive transcription of the skin gene SPRR2 in mice with an XPD/TTD mutation (de Boer et al., 1998b) , it is still possible that other gene(s) are dierentially transcribed in XPD cells. Current studies are aimed to assess the expression of genes associated with the repair of damaged DNA. Accumulation of p53 was observed concurrently at early time points after doxorubicin treatment in normal and XPD LCLs, indicating that the molecular basis for the delayed response to doxorubicin lies in factors downstream of p53 stabilization. In order to determine if resistance to apoptosis upon drug treatment in XPD LCLs was related to a defect in the irreversible activation of caspases responsible for the executioner phase of apoptosis, we assessed the appearance of PARP cleavage product in apoptosis mediated by Fasreceptor activation. We found no dierence in the time of appearance of cleaved product. Thus, the apoptotic machinery is functional in XPD cells, and their de®ciency must lie upstream of caspase activation. Furthermore, this result strengthens our observation that p53-mediated apoptosis is aected in XPD LCLs.
In summary, we have not found thus far a speci®c qualitative or quantitative dierence in transcription that can explain the delay and reduction in apoptosis observed in XPD cells in response to doxorubicin. Together with previous data regarding the binding of p53 to XPD in the TFIIH complex (Wang et al., 1996) , our results bring up the possibility that a p53-mediated transactivation-independent process can also contribute to p53-mediated apoptosis and be aected in XPD cells. Stabilized p53 may interact with the basal transcription machinery and promote apoptosis in the presence of DNA damage, possibly by modulating an activity that is essential for DNA repair. It has been reported that p53 can be phosphorylated by CAK, the cyclin-dependent kinase complex that is found bound to TFIIH (Ko et al., 1997; Lu et al., 1997) . It is also possible that initial damage recognition by TFIIH is aided by p53 binding to sites of DNA damage. The ultimate cellular response might be dependent on whether p53 is post-translationally modi®ed, by either phosphorylation or acetylation, and released from the complex in an activated state capable of sequence-speci®c transactivation of cell cycle checkpoint genes such as p21, or whether p53 remains bound to the helicase(s) in TFIIH and, through its inhibition of this activity, halts attempts to repair damaged DNA, thus initiating apoptosis.
Materials and methods
Cell culture
Normal LCLs GM01310B and HG1943, XPD LCLs GM03249, GM02253F, GM02485C and XPD heterozygote GM02473A were obtained from Coriell Cell Repositories (http://locus.umdnj.edu/nigms/). C3ABR is a normal LCL obtained from Dr KK Khanna (The Queensland Institute of Medical Research, University of Queensland, Australia). All XPD cell lines are compound heterozygotes that bear the following mutations in the XPD gene: GM03249, G602D and second allele not expressed; GM02253F, R683W and D681N; GM02485C, R683W and del exon3 (AR Lehmann and BC Broughton, personal communication) . GM02473A was derived from the clinically normal mother of patient GM02253F and has a single XPD mutation and a wildtype XPD allele. All LCLs were grown in suspension in RPMI 1640 plus 15% heat-inactivated FBS. Cultures were incubated with the indicated doses of doxorubicin (SIGMA, St. Louis, MO, USA) or 1 mg/ml Fas antibody CH-11 (Immunotech, France).
Transduction of LCLs with retroviral vectors
The retroviral vectors containing a neo marker with or without the full length HPV16 E6 gene cDNA were generously provided by Dr Denise Galloway (Fred Hutchinson Cancer Research Center, Seattle, WA, USA). The infectious virus was harvested from the virus-producing cell line PA317 grown in DMEM plus 10% FBS, ®ltered through a 0.45 mm ®lter, and stored in aliquots at 7708C. About 2610 6 exponentially growing target cells were pelleted and resuspended in a 4-ml infection cocktail containing 1 ml retrovirus stock, 3 ml RPMI 1640 plus 15% heat-inactivated FBS and 4 mg/ml polybrene (hexadimethrine bromide). After incubation at 378C for 2 h, 4 ml additional medium without polybrene was added and the incubation proceeded for a further 16 h. The viral vector was then removed, and the cells were resuspended in fresh medium without polybrene. Fortyeight hours after the start of the infection cells, they were transferred to medium containing G418 (Geneticin) at 0.5 mg/ml. Pools of retrovirally transduced cells were frozen and stored.
Assays for apoptosis and cell viability
Cells were seeded at 6.25610 5 cells/ml the night before the beginning of the experiment. Cell viability was assessed by trypan blue exclusion in triplicate and expressed as the fraction of living cells relative to the respective untreated control. Immuno¯uorescent detection of Annexin V-FITC binding (Oncogene Research Products, Cambridge, MA, USA) was performed according to instructions from the manufacturer and quantitated by¯ow cytometry using FACScan and Cell Quest Software (Becton Dickinson). The percentage of speci®c apoptosis was calculated as 1006(experimental apoptosis7spontaneous apoptosis)/ (1007spontaneous apoptosis). Apoptosis was also assessed on DAPI-stained paraformaldehyde-®xed cells by morphological evidence of DNA fragmentation.
Western blot analysis
At the indicated time points after treatment with doxorubicin, cells were lysed in buer containing 0.5% NP40, 150 mM NaCl, 2.5 mM EGTA, 1 mM EDTA, 10 mg/ ml aprotinin, 0.5 mM PMSF and 10 mg/ml leupeptin in 50 mM HEPES pH 7.5. Whole cell extracts containing 30 mg of protein, measured by the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA) were separated by 10 or 15% SDS ± PAGE, and electrotransferred onto a nitrocellulose membrane (Bio-Rad). For PARP analysis, frozen cell pellets were lysed and sonicated in buer containing 0.5% sodium deoxycholate, 0.2% SDS, 1% Triton X-100, 5 mM EDTA, 10 mg/ml aprotinin, 0.5 mM PMSF, and 10 mg/ml leupeptin in PBS (Whitacre and Berger, 1997). Samples containing 30 mg of protein were electrophoresed by 7.5% SDS ± PAGE, and electrotransferred onto a nitrocellulose membrane. The following primary antibodies were used for protein analysis by standard Western blotting procedures: monoclonal human p53 (Ab-6), monoclonal PCNA (Ab-1), monoclonal human p21 (Ab-1), and monoclonal PARP (Ab-2), all from Oncogene Science, monoclonal anti-actin clone C4 (Boehringer Mannheim, Indianapolis, IN, USA), and polyclonal Bax (N-20) (Santa Cruz Biotech., Santa Cruz, CA, USA).
RNAse protection assay
Cells were lysed with Trizol reagent (Gibco ± BRL, Gaithersburg, MD, USA), and total RNA was extracted according to manufacturer's instructions. Expression of apoptosis-related genes was studied by RNAse protection assay, using the RiboQuan TM Multi-Probe RNAse Protection Assay System (Pharmingen, San Diego, CA, USA). The hStress-1 multi-probe template set targets bcl-X, p53, GADD45, p21, bax, mcl1, c-fos, bcl-2, as well as the housekeeping genes, L32 and GAPDH. Quanti®cation of mRNA species was performed by densitometric analysis MacBas software (FUJIFILM).
